Zacks Investment Research on MSN8h
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...
Healio13d
FDA approves expanded label for Iluvien
The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis ...
The American Journal of Managed Care7d
Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC
said the FDA had not disclosed the reasons for the lack of approval this time around. 2 The current standard of care for frontline treatment of unresectable HCC is atezolizumab (Tecentriq ...
Morningstar1mon
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
“We are thrilled to receive Fast Track designation from the FDA,” said Sam Whiting ... study evaluating amezalpat plus standard-of-care atezolizumab and bevacizumab versus atezolizumab ...